{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:38:35Z","timestamp":1792521515738,"version":"4.5.0"},"reference-count":68,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre (Poland)","award":["2022\/06\/X\/NZ7\/00665"],"award-info":[{"award-number":["2022\/06\/X\/NZ7\/00665"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Empagliflozin (EMPA), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, prevents endothelial dysfunction, but its effects on vascular tone in hypertension remain unclear. This study investigated whether EMPA modulates vasomotor tone via sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK) pathways in spontaneously hypertensive rats (SHR) and controls (Wistar Kyoto rats, WKY). Functional (wire myography, organ bath) and biochemical (Western blot) studies were conducted on the third-order of the superior mesenteric arteries (sMAs) and\/or aortas. EMPA induced concentration-dependent relaxation of preconstricted sMAs in both groups. In SHR, EMPA enhanced acetylcholine (Ach)-induced relaxation in sMAs and aortas and reduced constriction induced by phenylephrine (Phe) and U46619 in sMAs. The SIRT1 inhibitor (EX527) abolished EMPA\u2019s effects on Ach-mediated relaxation and U46619-induced vasoconstriction, while AMPK inhibition reduced Ach-mediated relaxation and Phe-induced vasoconstriction. SHR showed increased SGLT2 and SIRT1 expression and decreased pAMPK\/AMPK levels in sMAs. In conclusion, EMPA might exert vasoprotective effects in hypertension by enhancing endothelium-dependent relaxation and reducing constriction via AMPK\/SIRT1 pathways. These properties could improve vascular health in patients with hypertension and related conditions. Further studies are needed to explore new indications for SGLT2 inhibitors.<\/jats:p>","DOI":"10.3390\/cells14070507","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:21:04Z","timestamp":1743398464000},"page":"507","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1\/AMPK Pathway"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7374-0999","authenticated-orcid":false,"given":"Monika","family":"Kloza","sequence":"first","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bia\u0142ystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-3757","authenticated-orcid":false,"given":"Anna","family":"Krzy\u017cewska","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bia\u0142ystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-3350","authenticated-orcid":false,"given":"Hanna","family":"Koz\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bia\u0142ystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1794-9947","authenticated-orcid":false,"given":"Sandra","family":"Budziak","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bia\u0142ystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-2656","authenticated-orcid":false,"given":"Marta","family":"Baranowska-Kuczko","sequence":"additional","affiliation":[{"name":"Department of Experimental Physiology and Pathophysiology, Medical University of Bia\u0142ystok, 15-222 Bia\u0142ystok, Poland"},{"name":"Department of Clinical Pharmacy, Medical University of Bia\u0142ystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e40536","DOI":"10.1097\/MD.0000000000040536","article-title":"Impact of sodium-glucose cotransporter inhibitors in acute coronary syndrome patients on endothelial function and atherosclerosis related-biomarkers: ATH-SGLT2i pilot study","volume":"103","author":"Abbassi","year":"2024","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Komaniecka, N., Maroszek, S., Drozdzik, M., Oswald, S., and Drozdzik, M. (2024). Transporter Proteins as Therapeutic Drug Targets\u2014With a Focus on SGLT2 Inhibitors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25136926"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kurczy\u0144ski, D., Hudzik, B., Jagosz, M., Zabierowski, J., Nowak, J., Tomasik, A., Badzi\u0144ski, A., Rozentryt, P., and G\u0105sior, M. (2022). Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9070225"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107832","DOI":"10.1016\/j.pharmthera.2021.107832","article-title":"Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors","volume":"224","author":"Ugusman","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_10","first-page":"cvae156","article-title":"Crucial role for sensory nerves and Na\/H exchanger inhibition in dapagliflozin and empagliflozin-induced arterial relaxation","volume":"26","author":"Forrester","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Li, X., Wang, M., Kalina, J.O., Preckel, B., Hollmann, M.W., Albrecht, M., Zuurbier, C.J., and Weber, N.C. (2024). Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis. Redox Biol., 69.","DOI":"10.1016\/j.redox.2023.102979"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107212","DOI":"10.1016\/j.vph.2023.107212","article-title":"Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions","volume":"152","author":"Neutel","year":"2023","journal-title":"Vasc. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Durante, W., Behnammanesh, G., and Peyton, K.J. (2021). Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168786"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hasan, A., and Hasan, R. (2021). Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K+ (KV) Channels. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910842"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e09503","DOI":"10.1016\/j.heliyon.2022.e09503","article-title":"Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels","volume":"8","author":"Hasan","year":"2022","journal-title":"Heliyon"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2147\/DMSO.S419125","article-title":"Empagliflozin Induces Vascular Relaxation in Rat Coronary Artery Due to Activation of BK Channels","volume":"17","author":"Kong","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.taap.2020.115153","article-title":"Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels","volume":"403","author":"Seo","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wicik, Z., Nowak, A., Jarosz-Popek, J., Wolska, M., Eyileten, C., Siller-Matula, J.M., von Lewinski, D., Sourij, H., Filipiak, K.J., and Postu\u0142a, M. (2020). Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.901340"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Tai, S., Zhang, N., Fu, L., and Wang, Y. (2023). Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115213"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"14855","DOI":"10.1073\/pnas.0704329104","article-title":"SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase","volume":"104","author":"Mattagajasingh","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1111\/febs.15863","article-title":"AMPK, metabolism, and vascular function","volume":"288","author":"Contreras","year":"2021","journal-title":"FEBS J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/1440-1681.13470","article-title":"Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1\/PTEN\/Akt pathway","volume":"48","author":"Tian","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1475-2840-9-5","article-title":"Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat","volume":"9","author":"Vahtola","year":"2010","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13961","article-title":"Interplay of adenosine monophosphate-activated protein kinase\/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework","volume":"22","author":"Packer","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/bph.14716","article-title":"Acute activation of endothelial AMPK surprisingly inhibits endothelium-dependent hyperpolarization-like relaxations in rat mesenteric arteries","volume":"176","author":"Chen","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 Inhibitors\u2014The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review","volume":"15","author":"Seidu","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kilkenny, C., Browne, W., Cuthill, I.C., Emerson, M., and Altman, D.G. (2010). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol., 8.","DOI":"10.1371\/journal.pbio.1000412"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1161\/HYP.0000000000000090","article-title":"Animal Models of Hypertension: A Scientific Statement from the American Heart Association","volume":"73","author":"Lerman","year":"2019","journal-title":"Hypertension"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Baranowska-Kuczko, M., Koz\u0142owska, H., Kloza, M., Kusaczuk, M., Harasim-Symbor, E., Biernacki, M., Kasacka, I., and Malinowska, B. (2021). Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111120"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00150","DOI":"10.1002\/prp2.150","article-title":"Reduced activity of SKC a and Na-K ATPase underlies the accelerated impairment of EDH-type relaxations in mesenteric arteries of aging spontaneously hypertensive rats","volume":"3","author":"Kong","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Krzy\u017cewska, A., Baranowska-Kuczko, M., Kasacka, I., and Koz\u0142owska, H. (2023). Cannabidiol alleviates right ventricular fibrosis by inhibiting the transforming growth factor \u03b2 pathway in monocrotaline-induced pulmonary hypertension in rats. Biochim. Biophys. Acta Mol. Basis Dis., 1869.","DOI":"10.1016\/j.bbadis.2023.166753"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ajh\/hpaa195","article-title":"Mechanisms of Vascular Remodeling in Hypertension","volume":"34","author":"Humphrey","year":"2021","journal-title":"Am. J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"123247","DOI":"10.1016\/j.lfs.2024.123247","article-title":"Transient cerebral ischaemia alters mesenteric arteries in hypertensive rats: Limited reversal despite suberoylanilide hydroxamic acid cerebroprotection","volume":"359","author":"Briones","year":"2024","journal-title":"Life Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107095","DOI":"10.1016\/j.vph.2022.107095","article-title":"Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2","volume":"146","author":"Bruckert","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects","volume":"2","author":"Seman","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.pharep.2019.06.004","article-title":"Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro","volume":"71","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11010-022-04633-8","article-title":"Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries","volume":"478","author":"Lascu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Korkmaz-Ic\u00f6z, S., Kocer, C., Sayour, A.A., Kraft, P., Benker, M.I., Abulizi, S., Georgevici, A.I., Brlecic, P., Radovits, T., and Loganathan, S. (2021). The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia\/Reperfusion Injury in Rats. Int. J. Mol. Sci., 22.","DOI":"10.1055\/s-0041-1725601"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e025328","DOI":"10.1161\/JAHA.121.025328","article-title":"Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling","volume":"11","author":"Zhao","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/ATVBAHA.110.210500","article-title":"Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway","volume":"30","author":"Ota","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bcp.2013.02.015","article-title":"SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: Implications for vascular aging","volume":"85","author":"Zarzuelo","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1113\/jphysiol.2011.211219","article-title":"SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans","volume":"589","author":"Donato","year":"2011","journal-title":"J. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, F., and Chen, H.Z. (2020). Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.537519"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jansen, T., Kvandov\u00e1, M., Daiber, A., Stamm, P., Frenis, K., Schulz, E., M\u00fcnzel, T., and Kr\u00f6ller-Sch\u00f6n, S. (2020). The AMP-Activated Protein Kinase Plays a Role in Antioxidant Defense and Regulation of Vascular Inflammation. Antioxidants, 9.","DOI":"10.3390\/antiox9060525"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1038\/s41467-022-32568-7","article-title":"AMPK deficiency in smooth muscles causes persistent pulmonary hypertension of the new-born and premature death","volume":"13","author":"Lewis","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"176543","DOI":"10.1016\/j.ejphar.2024.176543","article-title":"Resveratrol attenuates cyclosporin A-induced upregulation of the thromboxane A2 receptor and hypertension via the AMPK\/SIRT1 and MAPK\/NF-\u03baB pathways in the rat mesenteric artery","volume":"972","author":"Li","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18800","DOI":"10.18632\/oncotarget.4033","article-title":"Differential modulation of AMPK\/PPAR\u03b1\/UCP2 axis in relation to hypertension and aging in the brain, kidneys and heart of two closely related spontaneously hypertensive rat strains","volume":"6","author":"Rubattu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.cellsig.2011.06.019","article-title":"The specificities of small molecule inhibitors of the TGF\u00df and BMP pathways","volume":"23","author":"Vogt","year":"2011","journal-title":"Cell Signal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/0113816128289350240320063045","article-title":"Cellular and Mitochondrial Pathways Contribute to SGLT2 Inhibitors-mediated Tissue Protection: Experimental and Clinical Data","volume":"30","author":"Sanz","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhai, R., Liu, Y., Tong, J., Yu, Y., Yang, L., Gu, Y., and Niu, J. (2020). Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.826792"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxres\/tfad007","article-title":"Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis","volume":"12","author":"Chen","year":"2023","journal-title":"Toxicol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10787-023-01384-w","article-title":"Empagliflozin repurposing in Parkinson\u2019s disease; modulation of oxidative stress, neuroinflammation, AMPK\/SIRT-1\/PGC-1\u03b1, and wnt\/\u03b2-catenin pathways","volume":"32","author":"Mohammed","year":"2024","journal-title":"Inflammopharmacology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"ElBaset, M.A., Salem, R.S., Ayman, F., Ayman, N., Shaban, N., Afifi, S.M., Esatbeyoglu, T., Abdelaziz, M., and Elalfy, Z.S. (2022). Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK\/SIRT-1\/HIF-1\u03b1 Pathway in Halting Liver Fibrosis. Antioxidants, 11.","DOI":"10.3390\/antiox11112152"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"14382","DOI":"10.1080\/21655979.2022.2085583","article-title":"\u03b2-aminoisobutyric acid ameliorates hypertensive vascular remodeling via activating the AMPK\/SIRT1 pathway in VSMCs","volume":"13","author":"Yin","year":"2022","journal-title":"Bioengineered"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kab\u0142ak-Ziembicka, A., Badacz, R., and Przew\u0142ocki, T. (2022). Clinical Application of Serum microRNAs in Atherosclerotic Coronary Artery Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11226849"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1567202613666161129112822","article-title":"Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease","volume":"14","author":"Maiese","year":"2017","journal-title":"Curr. Neurovasc. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.14336\/AD.2020.1229","article-title":"The Role of SGLT2 Inhibitors in Vascular Aging","volume":"12","author":"Liu","year":"2021","journal-title":"Aging Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-019-01796-8","article-title":"Skeletal muscle miR-34a\/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis","volume":"97","author":"Afonso","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"C1573","DOI":"10.1152\/ajpcell.00351.2023","article-title":"Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat","volume":"326","author":"Castro","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41440-024-01723-6","article-title":"The relationship between SGLT2 and systemic blood pressure regulation","volume":"47","author":"Ahwin","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mira Hernandez, J., Shen, E.Y., Ko, C.Y., Hourani, Z., Spencer, E.R., Smoliarchuk, D., Bossuyt, J., Granzier, H., Bers, D.M., and Hegyi, B. (2024). Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic HFpEF model. Cardiovasc. Res., cvae070. epub ahead of print.","DOI":"10.1093\/cvr\/cvae070"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: The statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Piechocki, M., Przew\u0142ocki, T., Pieni\u0105\u017cek, P., Trystu\u0142a, M., Podolec, J., and Kab\u0142ak-Ziembicka, A. (2024). A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients\u2014A Review PART II-Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory. J. Clin. Med., 13.","DOI":"10.3390\/jcm13051508"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/7\/507\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:18Z","timestamp":1760029518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/7\/507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":68,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cells14070507"],"URL":"https:\/\/doi.org\/10.3390\/cells14070507","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}